title: International survey of awareness of genetic risk in the clinical sarcoma community.
abstract: OBJECTIVE
  Integration of clinical genetics into oncology is variable. Sarcomas have a strong genetic component, with up to 1/30 patients carrying germline TP53 mutations. This study aimed to define genetic risk awareness among sarcoma physicians. Outcomes were attitudes toward genetic testing, level of cancer risk and awareness of risk reduction measures.
  
  
  METHODS
  An online survey was administered to members of the Connective Tissue Oncology Society and the Australasian Sarcoma Study Group.
  
  
  RESULTS
  Sarcoma physicians (N = 124) from 21 countries participated, 40% of whom favored TP53 mutation testing in children regardless of family history, increasing to ∼83% for all age groups if a family history was present and ∼85% if multiple primary cancers were present. However, 33% were not aware that risk reduction strategies might identify some cancers at a more curable stage in carriers.
  
  
  CONCLUSIONS
  Clinical genetics is not yet standard of care for multidisciplinary management of sarcoma. Awareness of genetic risk is important among sarcoma physicians. Attitudes among the sarcoma community were generally positive, but education on genetic risk in sarcoma patients and collaboration with clinical genetics services might improve quality of care. Sarcoma physicians need routine access to clinical genetics services so that potential germline TP53 mutation carriers are recognized.
authors.affiliation: School of Public Health, Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.|The Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
authors.forename: Kate A
authors.initials: KA
authors.lastname: McBride
authors.affiliation: School of Public Health, Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Schlub
authors.affiliation: Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Mandy L
authors.initials: ML
authors.lastname: Ballinger
authors.affiliation: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
authors.forename: David M
authors.initials: DM
authors.lastname: Thomas
authors.affiliation: Department of Cancer Medicine, The Chris O'Brien Lifehouse, Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.
authors.forename: Martin Hn
authors.initials: MH
authors.lastname: Tattersall
mesh_terms: D000328:Adult; D005260:Female; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D008875:Middle Aged; D010820:Physicians; D012509:Sarcoma / Q000235:genetics*; D011795:Surveys and Questionnaires; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D055815:Young Adult
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
keywords: attitude; genes; hereditary cancer syndromes; neoplasm; physician practice patterns; sarcoma